Our Pipeline

Robust Pipeline Focused on Advancing ROCK Inhibitor Portfolio

Our Pipeline

Target/Product

Indications

Research

Preclinical

Phase 1

Phase 2

Status / Rights

Proprietary (Fibrosis)

Idiopathic pulmonary fibrosis (IPF)

Phase 2a study
Complete

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Cancer-associated fibrosis, MASH, cGvHD

Phase 1b/2 commencements
2025

Fibrostenotic Crohn’s Disease

Phase 2 study start
H2 2025

DDR1 Inhibitor
(RXC009)

Kidney fibrosis, Lung fibrosis

IND/CTA submission
2025

Proprietary
(Oncology)

Porcupine Inhibitor
Zamaporvint(RXC004)

Wnt-ligand driven GI-tumours – combination

Data reported 2024
Partnership candidate

Partnered

Pan-RAF Inhibitor
(JZP815)

Oncology

KRAS Inhibitors
(Pan-KRAS)

Oncology

Porcupine Inhibitor
(RXC006/AZD5055)

Undisclosed non-oncoloqv

cGvHD: Chronic Graft Versus Host Disease; CTA: Clinical trial application; DDR1: Discoidin Domain Receptor 1; GI: Gastrointestinal; IND: Investigational new drug application; MASH: Metabolic dysfunction–associated steatohepatitis; RAF: Rapidly accelerated fibrosarcoma; ROCK: Rho associated protein kinase

Proprietary (Fibrosis)
Phase 2

Idiopathic pulmonary fibrosis (IPF)

STATUS / RIGHTS

Phase 2a study
Complete

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Preclinical

Cancer-associated fibrosis, MASH, cGvHD

STATUS / RIGHTS

Phase 1b/2 commencements
2025

Phase 1

Fibrostenotic Crohn’s Disease

STATUS / RIGHTS

Phase 2 study start
H2 2025

DDR1 Inhibitor
(RXC009)

Preclinical

Kidney fibrosis, Lung fibrosis

STATUS / RIGHTS

IND/CTA submission
2025

Proprietary
(Oncology)

Porcupine Inhibitor
Zamaporvint(RXC004)

Phase 2

Wnt-ligand driven GI-tumours – combination

STATUS / RIGHTS

Data reported 2024
Partnership candidate

Partnered

Pan-RAF Inhibitor
(JZP815)

Phase 1

Oncology

KRAS Inhibitors
(Pan-KRAS)

Research

Oncology

Porcupine Inhibitor
(RXC006/AZD5055)

Research

Undisclosed non-oncoloqv

cGvHD: Chronic Graft Versus Host Disease; CTA: Clinical trial application; DDR1: Discoidin Domain Receptor 1; GI: Gastrointestinal; IND: Investigational new drug application; MASH: Metabolic dysfunction–associated steatohepatitis; RAF: Rapidly accelerated fibrosarcoma; ROCK: Rho associated protein kinase